SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 5,411 Shares of Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 5,411 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $17.06, for a total transaction of $92,311.66. Following the completion of the transaction, the chief executive officer owned 356,730 shares of the company’s stock, valued at $6,085,813.80. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Laura Francis also recently made the following trade(s):

• On Monday, August 18th, Laura Francis sold 11,343 shares of SiBone stock. The shares were sold at an average price of $15.60, for a total value of $176,950.80.

SiBone Trading Down 0.8%

SIBN stock traded down $0.14 during mid-day trading on Friday, reaching $17.12. The company’s stock had a trading volume of 285,942 shares, compared to its average volume of 434,386. The company has a market cap of $742.97 million, a price-to-earnings ratio of -33.57 and a beta of 0.81. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The company has a current ratio of 7.97, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average price is $15.30 and its 200 day moving average price is $16.60.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The firm had revenue of $48.66 million during the quarter, compared to the consensus estimate of $46.67 million. SiBone has set its FY 2025 guidance at EPS. On average, equities research analysts predict that SiBone will post -0.78 EPS for the current year.

Hedge Funds Weigh In On SiBone

A number of institutional investors have recently bought and sold shares of the business. Harbor Capital Advisors Inc. lifted its position in shares of SiBone by 7.7% in the second quarter. Harbor Capital Advisors Inc. now owns 573,705 shares of the company’s stock valued at $10,797,000 after acquiring an additional 40,993 shares in the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of SiBone during the second quarter valued at approximately $577,000. Goldman Sachs Group Inc. lifted its stake in shares of SiBone by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after purchasing an additional 83,919 shares in the last quarter. Trexquant Investment LP raised its stake in shares of SiBone by 31.1% in the 1st quarter. Trexquant Investment LP now owns 115,114 shares of the company’s stock valued at $1,615,000 after purchasing an additional 27,331 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in SiBone by 55.0% in the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock valued at $8,861,000 after purchasing an additional 224,190 shares during the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SIBN has been the subject of several analyst reports. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Cantor Fitzgerald set a $25.00 target price on SiBone and gave the company an “overweight” rating in a report on Monday, August 11th. Truist Financial decreased their price target on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.